Phacoemulsification surgery in patients with diabetic macular edema: should intravitreal anti-VEGF therapy be performed before or simultaneously with surgery?
Yazarlar (4)
Doç. Dr. Yusuf Ziya Güven İzmir Kâtip Çelebi Üniversitesi, Türkiye
Mehmed Uğur Işık
Kastamonu Üniversitesi, Türkiye
Serdar İlgüy
Kastamonu Üniversitesi, Türkiye
Doç. Dr. Zübeyir YOZGAT Kastamonu Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı International Journal of Ophthalmology (Q3)
Dergi ISSN 2222-3959 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili Türkçe Basım Tarihi 04-2025
Cilt / Sayı / Sayfa 18 / 4 / 637–641 DOI 10.18240/ijo.2025.04.09
Makale Linki https://doi.org/10.18240/ijo.2025.04.09
UAK Araştırma Alanları
Göz Hastalıkları
Özet
AIM To investigate the optimal anti-vascular endothelial growth factor (VEGF) treatment time in patients with diabetic macular edema (DME) scheduled for cataract surgery. METHODS The study was designed to include 4 groups. Twenty-six eyes of 26 patients with diabetes but no retinopathy (DR; group 1), 17 eyes of 17 patients with DR but no DME (group 2), and 19 eyes of 19 patients with DME who received anti-VEGF therapy concurrently with cataract surgery (group 3), and 21 eyes of 21 patients who received anti-VEGF therapy for DME 1wk before cataract surgery (group 4). The patients' best corrected visual acuity, intraocular pressure, central and mean macular thickness (CMT and MMT) values were noted on the day of surgery, postoperative day 1, week 1, and month 1. RESULTS There was a significant increase of CMT after cataract surgery in groups 1, 2, and 3 (P<0.001, P=0.044, and P=0.034 …
Anahtar Kelimeler
cataract surgery | diabetic macular edema | timing of anti-vascular endothelial growth factor therapy